ClinicalTrials.gg
RecruitingNCT05843786IGNORANTUpdated Jul 6, 2026

Human Recombinant Interferon Gamma in the Treatment of Ventilator-acquired Pneumonia in ICU Patients

A Phase 3 interventional study of Interferon gamma and Placebo in Pneumonia, Ventilator-Associated, sponsored by Hospices Civils de Lyon. Recruiting at 9 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-06.

Sponsored by Hospices Civils de Lyon · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
132
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 80 studies in Pneumonia, Ventilator-Associated with a site in France — 20 open to participants now, 22 under way, 3 of them phase 3. Pneumonia, Ventilator-Associated · France.

Planned enrollment
27th of 47
132 · median 161
Started
2023
with 7 others
Phase 3
16 of 80
3 open now
Primary completion
2027-07
later than 13 of 21 live
Registered
61st of 80
by date

Among the 80 studies in Pneumonia, Ventilator-Associated with a site in France, this one is the 27th largest by planned enrollment of the 47 interventional ones that give a count, is one of 8 that started in 2023, is one of 16 in phase 3, reaches primary completion later than 13 of the 21 other live ones, and was the 61st registered.

Pneumonia, Ventilator-Associated

420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.

Browse Pneumonia, Ventilator-Associated studies →

Open to participants now

20 of the 80 studies in Pneumonia, Ventilator-Associated with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 80 studies in Pneumonia, Ventilator-Associated with a site in France, or all of them as a file.
02

Study summary

Clinical presentation of patients after severe injury such as a severe infection, trauma or extensive burns is characterized by the simultaneous occurrence of dysregulation of the initial inflammatory response and immunosuppression associating quantitative and functional alterations of innate and adaptive immune cells. These acquired immune dysfunctions have been associated with an increased susceptibility to nosocomial infections, foremost among which are ventilator-associated pneumonia (VAP). Despite the implementation of a set of preventive measures, the incidence of these VAP remains high in intensive care, with rates in Europe of 1.5% per day of ventilation.

Post-aggressive immunosuppression is characterized by the decrease in the expression of HLA-DR (belonging to the type II major histocompatibility complex, MHC-II) on the surface of monocytes (mHLA-DR). The administration of interferon gamma (IFNγ) can restore the level of mHLA-DR and may possibly improve the prognosis as an adjuvant therapy associated to antibiotics. However, the level of proof of this therapeutic strategy is low, limited to small cohorts of patients, or clinical studies without prior immunodepression assessment. The objective of this study is to conduct a randomized, double-blind, placebo-controlled superiority trial to assess the effect of IFNγ administration on the duration of mechanical ventilation following the first episode of VAP in patients having an HLA-DR \< 8000 AB/C

All reported data about recombinant human IFNγ 1b for the control of secondary infections in patients with septic shock used the dose of 100 micrograms per day by subcutaneous route for 3 to 5 days . At this dose, no retrospective study has reported any serious adverse effects and recombinant human IFNγ 1b allows an increase in monocyte membrane expression of mHLA-DR.

03

Conditions studied

  • Pneumonia, Ventilator-Associated

Keywords

  • Critical Illness
  • Interferon-gamma
  • Immunodepression
  • Sepsis
  • Trauma
  • Monocyte HLA-DR
  • immunostimulation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • adult patients hospitalized in intensive care unit
  • under mechanical ventilation for more than 5 days
  • having a first episode of VAP (with a Clinical Pulmonary Infectious Score (CPIS score) >6)
  • treated with antibiotics for less than 24 hours
  • with monocyte HLA-DR \< 8000 AB/C
  • written signed by the patient's trusted support person, or in the absence of the patient's representative and taking into account the agreement of the relative obtained by telephone emergency certificate completed and signed by the investigator
  • membership of a social security scheme

Exclusion criteria

Exclusion Criteria:

  • inability to administer the first dose of treatment in the study within 48 hours of the start of antibiotic therapy (antibiotic therapy for VAP)
  • Noradrenaline > 0.25 mcg/kg/min
  • , defined by:

    • solid tumor with chemotherapy in the last 3 months
    • progressive disease
    • hematological disease
    • solid organ transplantation
    • infection (AIDS stage or not)
    • therapy at any dose for more than 3 months
    • ≥ 1 mg/kg of Prednisone equivalent for more than 7 days
    • immunosuppressive therapy
  • Head and/or cervical spine trauma : with a predictable impact on the duration of mechanical ventilation (left to the investigator's judgement), the investigator will assess whether the patient meets the following neurological criteria for extubation during their recovery:
  • A level of consciousness assessed as 0 or 1 on the Richmond Agitation-Sedation Scale (RASS)
  • FiO2 \<40%
  • PEEP level \<5 cmH2O
  • A FR/Vt ratio \<105
  • Effective cough
  • Response to simple commands
  • Administration of noradrenaline \< 0.2 mcg/kg/min
  • Cardiocirculatory arrest
  • Burn patient
  • Cirrhosis with Child B or C score
  • Infection with Aspergillus spp.
  • Refusal to participate
  • Patient participating in another interventional research in progress or including an exclusion period still in progress at pre-inclusion (excluding interventional research of 2° not interfering with the endpoints of the study according to the judgment of the principal investigator)
  • Lack of social coverage
  • Patient under curatorship or guardianship
  • Pregnant or breastfeeding women
  • Patient admitted to intensive care for SARS-Cov2 pneumonia
  • Known allergy to latex
  • to the active substance (interferon gamma-1b) or known hypersensitivity to related products, such as another interferon, or to any of the following : Mannitol, Disodium succinate hexahydrate, Succinic acid, polysorbate 20
  • Existence of chronic heart disease with FeVG\<45%
  • Major hepatic impairment (total >60 mg/L or 102 mcmol/L, equivalent to 3 SOFA points)
  • thrombocytopenia \<50000/mm3 (equivalent to 3 SOFA points) and/or ALT > 5N Lipase > 3N Severe chronic renal failure ( \< 10 ml/min/1.73m2)
  • Thrombocytopenia \<50,000/mm3 (equivalent to 3 SOFA points)
  • Respiratory failure requiring home oxygen therapy
  • Persons under court protection
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
132 participants (estimated)

Study arms

  • Experimental
    Interferon gamma treatment

    Interferon gamma treatment (100 micrograms /day during 5 days)

    Drug: Interferon gamma

  • Placebo comparator
    Placebo

    The comparator drug (placebo) is an injectable solution of sodium chloride 0.9%

    Drug: Placebo

Interventions

  • Daily subcutaneous administration of Interferon gamma during 5 days

  • DrugPlacebo

    Placebo during 5 days

06

What researchers measure

Primary outcomes

  1. duration of mechanical ventilation assessed from the first day of VAP diagnosis

    mechanical ventilation-free days (VFD) from extubation through D28. A beneficial effect of using recombinant human interferon gamma-1b would be a statistically significant increase in VFD in patients receiving study drug in this setting compared to the group receiving placebo.

    Time frame: Day 28

Secondary outcomes

  1. All-cause mortality in intensive care

    Time frame: Day 28

  2. Previous positive microbiological sample at inclusion becomes negative

    Previous positive microbiological sample at inclusion becomes negative, i.e. pulmonary, urinary, blood cultures

    Time frame: Day 5

  3. Length of stay in intensive care unit

    Time frame: Day 28

  4. length of stay at hospital

    Time frame: Day 28

  5. occurrence of another episode of VAP before extubation

    Time frame: Day 28

  6. occurrence of another episode of infection acquired in intensive care unit

    Time frame: Day 28

  7. increase of monocytic HLA-DR expression above 8000 AB/C the day after the last dose of treatment (J5)

    Time frame: Day 28

  8. increase or decrease of blood leucocyte count at the day after the last dose of treatment (J5) in comparison to baseline

    Time frame: Day 28

  9. Evaluation of the economic efficiency of the administration of IFN-γ (assessed by the ACER (average cost-effectiveness ratio) method)

    Evaluation of the cost-effectiveness of IFN-γ administration (assessed by the ACER (average cost-effectiveness ratio) method)

    Time frame: Day 28

07

Study locations

4 of 9 sites recruiting
  • CHU Limoges
    Limoges, France
    Not yet recruiting
    • Olivier PLATEKER, MD · Contact
    • Olivier PLATEKER, MD · Principal investigator
  • Service civilo-militaire d'Anesthésie-Réanimation et Médecine Périopératoire
    Lyon, 69003, France
    Recruiting
    • Anne-Claire LUKASZEWICZ, Pr · Contact
    • Anne-Claire LUKASZEWICZ, Pr · Principal investigator
  • Service de reanimation chirurgicale Hopital Croix-Rousse
    Lyon, 69004, France
    Not yet recruiting
  • Service de reanimation médicale hôpital de la Croix-Rousse
    Lyon, 69004, France
    Recruiting
  • Hôpital Edouard Herriot - Médecine intensive - réanimation
    Lyon, France
    Not yet recruiting
    • Laurent ARGAUD, MD · Contact
    • Laurent ARGAUD, MD · Principal investigator
  • Service d'anesthésie-réanimation, unité de réanimation chirurgicale Picard
    Nancy, 54511, France
    Not yet recruiting
    • Marie-Reine Marie-Reine LOSSER, Pr · Contactmr.losser@chru-nancy.fr · 3 83 15 41 66
    • Marie-Reine LOSSER, Pr · Principal investigator
  • Médecine intensive- Réanimation
    Paris, 75014, France
    Recruiting
    • Frederic PENE, Pr · Contactfrederic.pene@aphp.fr · 1 58 41 25 36
    • Frederic PENE, Pr · Principal investigator
  • Service d'Anesthésie-réanimation-médecine intensive Hôpital Lyon Sud
    Pierre-Bénite, 69395, France
    Recruiting
  • Département Anesthésie-Réanimation
    Saint-Etienne, 42055, France
    Not yet recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2023 (actual). Primary completion is estimated for Jul 2027, 49 months after the start.

Of 16 phase 3 interventional studies under Pneumonia, Ventilator-Associated, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 59. This study's planned 49 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2023
First posted
May 6, 2023
StartActual
Jun 30, 2023
Primary completionEst.
Jul 30, 2027
CompletionEst.
Jul 30, 2027
Last update
Jul 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05843786
Responsible party
Sponsor
First posted
May 6, 2023
Start date
Jun 30, 2023
Primary completion
Jul 30, 2027 (estimated)
Completion
Jul 30, 2027 (estimated)
Last update
Jul 6, 2026

Study contacts

Anne-Claire LUKASZEWICZ, Pr
Contact
anne-claire.lukaszewicz@chu-lyon.fr
472 11 13 27 ext. +33
Camille BOUCHENY
Contact
Camille.boucheny@chu-lyon.fr
4 26 73 27 39 ext. +33
Anne-Claire LUKASZEWICZ, Pr
principal investigator · Hospices Civils de Lyon

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Interferon Gamma

Start the discussion